BIT:BIO2

Stock Analysis Report

Executive Summary

BioDue S.p.A. develops, manufactures, and markets cosmetics, food supplements, and medical devices.

Snowflake

Fundamentals

Excellent balance sheet with reasonable growth potential.

Share Price & News

How has BioDue's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0.6%

BIO2

-0.5%

IT Personal Products

0.6%

IT Market


1 Year Return

27.6%

BIO2

18.4%

IT Personal Products

15.3%

IT Market

Return vs Industry: BIO2 exceeded the Italian Personal Products industry which returned 18.4% over the past year.

Return vs Market: BIO2 exceeded the Italian Market which returned 15.3% over the past year.


Shareholder returns

BIO2IndustryMarket
7 Day0.6%-0.5%0.6%
30 Day0.6%-2.1%1.0%
90 Day20.0%-1.8%1.0%
1 Year30.0%27.6%21.1%18.4%20.6%15.3%
3 Year53.5%47.3%48.9%38.9%27.0%8.2%
5 Yearn/a106.5%84.0%21.3%-26.1%

Price Volatility Vs. Market

How volatile is BioDue's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is BioDue undervalued compared to its fair value and its price relative to the market?

6.1%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: BIO2 (€6.48) is trading below our estimate of fair value (€6.9)

Significantly Below Fair Value: BIO2 is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: BIO2 is good value based on its PE Ratio (18.7x) compared to the Personal Products industry average (21.8x).

PE vs Market: BIO2 is poor value based on its PE Ratio (18.7x) compared to the Italian market (17.8x).


Price to Earnings Growth Ratio

PEG Ratio: BIO2 is good value based on its PEG Ratio (0.8x)


Price to Book Ratio

PB vs Industry: BIO2 is overvalued based on its PB Ratio (3.3x) compared to the XE Personal Products industry average (1.9x).


Next Steps

Future Growth

How is BioDue forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

22.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BIO2's forecast earnings growth (22.3% per year) is above the savings rate (2.9%).

Earnings vs Market: BIO2's earnings (22.3% per year) are forecast to grow faster than the Italian market (8.4% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: BIO2's revenue (9.6% per year) is forecast to grow faster than the Italian market (3% per year).

High Growth Revenue: BIO2's revenue (9.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: BIO2's Return on Equity is forecast to be low in 3 years time (19.4%).


Next Steps

Past Performance

How has BioDue performed over the past 5 years?

19.9%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: BIO2's earnings have grown by 19.9% per year over the past 5 years.

Accelerating Growth: BIO2's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: BIO2 had negative earnings growth (-17.2%) over the past year, making it difficult to compare to the Personal Products industry average (3.1%).


Return on Equity

High ROE: BIO2's Return on Equity (16%) is considered low.


Return on Assets

ROA vs Industry: BIO2 has a higher Return on Assets than the Personal Products industry average last year.


Return on Capital Employed

ROCE Improving: BIO2's Return on Capital Employed has declined over the past 3 years.


Next Steps

Financial Health

How is BioDue's financial position?


Financial Position Analysis

Short Term Liabilities: BIO2's short term assets (€23.8M) exceeds its short term liabilities (€14.0M)

Long Term Liabilities: BIO2's short term assets (23.8M) exceeds its long term liabilities (12.8M)


Debt to Equity History and Analysis

Debt Level: BIO2's debt to equity ratio (54.4%) is considered high

Reducing Debt: BIO2's debt to equity ratio has reduced from 91.9% to 54.4% over the past 5 years.

Debt Coverage: BIO2's debt is well covered by operating cash flow (28.4%).

Interest Coverage: BIO2's interest payments on its debt are well covered by EBIT (65.9x coverage).


Balance Sheet

Inventory Level: BIO2 has a high level of physical assets or inventory.

Debt Coverage by Assets: BIO2's debt is covered by short term assets (assets are 1.8x debt).


Next Steps

Dividend

What is BioDue's current dividend yield, its reliability and sustainability?

1.54%

Current Dividend Yield


Dividend Yield vs Market

company1.5%marketbottom25%2.1%markettop25%4.4%industryaverage2.2%forecastin3Years2.0%

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: BIO2's dividend (1.54%) isn’t notable compared to the bottom 25% of dividend payers in the Italian market (2.08%).

High Dividend: BIO2's dividend (1.54%) is low compared to the top 25% of dividend payers in the Italian market (4.4%).

Stable Dividend: Whilst dividend payments have been stable, BIO2 has been paying a dividend for less than 10 years.

Growing Dividend: BIO2's dividend payments have increased, but the company has only paid a dividend for 3 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonably low payout ratio (28.8%), BIO2's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: BIO2's dividends in 3 years are forecast to be well covered by earnings (27.5% payout ratio).


Next Steps

Management

What is the CEO of BioDue's salary, the management and board of directors tenure and is there insider trading?


CEO

Vanni Benedetti (51yo)

9.8yrs

Tenure

0

Mr. Vanni Benedetti serves as the Chairman of the Board of Directors at BioDue S.p.A. and has been its Chief Executive Officer since 2010 and its Director since 1993. 


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Vanni Benedetti (51yo)

    Chairman of the Board of Directors & CEO

    • Tenure: 9.8yrs

Board Members

  • Vanni Benedetti (51yo)

    Chairman of the Board of Directors & CEO

    • Tenure: 9.8yrs
  • Roberto Nisica

    Director

    • Tenure: 0yrs
  • Enrico Russo

    Vice Chairman of the Board

    • Tenure: 0yrs
  • Luca Sforazzini

    Director

    • Tenure: 0yrs
  • Conti Luciano

    Chairman of the Board of Statutory Auditors

    • Tenure: 0yrs
  • Bartolini Alfredo

    Statutory Auditor

    • Tenure: 0yrs
  • Bagnoli Luca

    Statutory Auditor

    • Tenure: 0yrs

Company Information

BioDue S.p.A.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: BioDue S.p.A.
  • Ticker: BIO2
  • Exchange: BIT
  • Founded: 1986
  • Industry: Personal Products
  • Sector: Household
  • Market Cap: €71.850m
  • Shares outstanding: 11.09m
  • Website: https://www.biodue.com

Location

  • BioDue S.p.A.
  • Via Ambrogio Lorenzetti, 3/a
  • Sambuca
  • Tavarnelle Val di Pesa
  • Florence
  • 50028
  • Italy

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BIO2BIT (Borsa Italiana)YesShares CapitalITEURMay 2015

Biography

BioDue S.p.A. develops, manufactures, and markets cosmetics, food supplements, and medical devices. The company produces liquid and solid food supplements, cosmetics, medical devices, and herbal products o ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/22 21:57
End of Day Share Price2019/10/22 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.